Management of Kawasaki disease: Corticosteroids revisited

The Lancet

Volumn 379, Issue 9826, 2012, Pages 1571-1572

  Son, Mary Beth F ^a   Newburger, Jane W ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE;

CORONARY ARTERY ANEURYSM; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; DRUG EFFICACY; FEVER; HIGH RISK PATIENT; HUMAN; MUCOCUTANEOUS LYMPH NODE SYNDROME; NOTE; PRIORITY JOURNAL; RISK REDUCTION; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84860315872     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60196-2     Document Type: Note

References (15)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967; 16: 178-222 (in Japanese).
2. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110: 2747-71.
3. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633-39.
4. Burns JC, Mason WH, Hauger SB, et al. Infl iximab treatment for refractory Kawasaki syndrome. J Pediatr 2005; 146: 662-67.
5. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996; 128: 146-49.
6. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000; 105: E78.
7. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979; 63: 175-79.
8. Shinohara M, Sone K, Tomomasa T, Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999; 135: 465-69.
9. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006; 149: 336-41.
10. Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003; 142: 611-16.
11. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of ulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356: 663-75.
12. Athappan G, Gale S, Ponniah T. Corticosteroid therapy for primary treatment of Kawasaki disease-weight of evidence: a meta-analysis and systematic review of the literature. Cardiovasc J Afr 2009; 20: 233-36.
13. Kobayashi T, Saji T, Otani T, et al, on behalf of the RAISE study group investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; published online March 8. DOI:10.1016/S0140-6736(11)61930-2.
14. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113: 2606-12.
15. Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011; 158: 831-35.